-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shisi Pharmaceutical: 6,000 Boxes of Antiviral Medication Delivered to Wuhan’s “Two Mountains” Hospitals
Category:
发布时间：2020-02-10
【概要描述】
“General Manager Zhu, Leishenshan Hospital began admitting patients last night, and the 3,000 boxes of Arbidol delivered to the hospital have already arrived. Please rest assured,” a representative from a Wuhan-based pharmaceutical company called Zhu Zhiyong, Deputy General Manager in charge of new-product sales at Shijiazhuang Sihua Pharmaceutical Co., Ltd., early on February 9 to report the situation.
“Mr. Zhu, last night Leishenshan Hospital began admitting patients, and the 3,000 boxes of Arbidol we delivered to the hospital have already arrived. Please rest assured,” a representative from a Wuhan-based pharmaceutical company called Zhu Zhiyong, Deputy General Manager in charge of new-product sales at Shijiazhuang Sihua Pharmaceutical Co., Ltd., early on February 9 to report the situation. This marks the first time that Sihua Pharmaceutical has supplied 3,000 boxes—totaling 72,000 capsules—of arbidol hydrochloride to both Wuhan’s Huoshenshan Hospital and Leishenshan Hospital for clinical antiviral treatment.
In late January this year, medical institutions and state-owned pharmaceutical trading enterprises in Wuhan, Hubei Province, and other regions contacted Shisi Pharmaceutical, requesting emergency supplies of antiviral Arbidol capsules and antibacterial intravenous infusions such as moxifloxacin hydrochloride sodium chloride injection.
Employees at the abidor production line’s blister-packaging station in the oral dosage-form workshop of Shijiazhuang Sihua Pharmaceutical are working diligently.
“What the front lines of prevention and control need, we will do our utmost to provide—overcoming every obstacle and exhausting every possible means to ensure the supply of key medicines for epidemic prevention and control, thereby contributing to the national effort to contain the pandemic. This is the responsibility and mission of those of us in the pharmaceutical industry,” said Su Xuejun, Chairman of Shisi Pharmaceutical.
Employees at the packaging station of the Arbidol production line in the oral dosage-form workshop at Shijiazhuang Sihua Pharmaceutical are stepping up production.
“The epidemic is an order, and ensuring supply is our responsibility.” Upon receiving the directive, Shisi Pharmaceutical immediately adjusted its production schedule, mobilized personnel and raw and auxiliary materials by all possible means, and ramped up the manufacture of emergency medicines and products such as Arbidol Hydrochloride Capsules, Moxifloxacin Hydrochloride Sodium Chloride Injection, sterile water, and disinfectants. The oral dosage-form production workshop’s Arbidol Capsule line, tasked with emergency supply assurance, has been operating at full capacity to do everything possible to meet clinical and market demand in Hubei Province and other regions.
To secure Abidor raw-material supplies through multiple channels and diversify supply sources, Shisi Pharmaceutical urgently submitted an application to the Hebei Provincial Drug Administration for the addition of a new API supplier to its registration. In response, the Hebei Provincial Drug Administration promptly established a “green channel” to provide full support for the company’s expansion of finished-product manufacturing capacity. Following successful product testing, the agency promptly approved Shisi Pharmaceutical’s supplemental application to add the new API supplier.
Shijiazhuang Sihua Pharmaceutical has developed and manufactured the anti-influenza viral drug Abidor Hydrochloride Capsules.
Since January 25, the first day of the Lunar New Year, Shisi Pharmaceutical has cumulatively shipped 1.36 million capsules of the antiviral drug arbidol hydrochloride to Hubei Province, including 960,000 capsules destined for Wuhan; 268,000 vials of the antibacterial drug moxifloxacin hydrochloride sodium chloride injection to Hubei, with 230,000 vials earmarked for Wuhan; and 378,000 bags (or bottles) of sterile water and basic intravenous solutions, thereby providing robust support for the supply of essential medicines on the front lines of epidemic prevention and control.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091